NASDAQ · Biotechnology

CABA (CABA) Stock

$2.71 -2.17% NASDAQ: CABA Healthcare

Valuation

MetricValue
Price$2.71
Market Cap$441.88M
P/E Ratio-2.23
P/B Ratio3.14
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$4.23
52-Week Low$1.26
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-150.00%
ROA-101.82%
ROCE-153.57%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.26
Current Ratio2.78

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-46.0M$-54.0M$-75.0M$-125.0M$-172.0M
Net Profit$-46.0M$-53.0M$-68.0M$-116.0M$-168.0M
EPS$-1.80$-1.81$-1.65$-2.34$-1.64
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$126.0M$117.0M$254.0M$185.0M$165.0M
Total Liabilities$8.0M$12.0M$17.0M$33.0M$53.0M
Cash$122.0M$82.0M$193.0M$164.0M$83.0M
Borrowings$0$5.0M$5.0M$16.0M$27.0M

Latest News

Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup Insider Monkey · Jun 17, 2026 FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases Exec Edge · Jun 9, 2026 Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D Business Wire · Jun 9, 2026 Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases Insider Monkey · Jun 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-34.0M$-46.0M$-54.0M$-88.0M$-131.0M
Investing Cash Flow$5.0M$-30.0M$-23.0M$45.0M$-51.0M
Financing Cash Flow$1.0M$0$2.0M$2.0M$0
Net Cash Flow$21.0M$-41.0M$112.0M$-29.0M$-81.0M
Free Cash Flow$-35.0M$-49.0M$-54.0M$-90.0M$-132.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-40.78%
Quick Ratio2.95
Interest Coverage-86.00
Return 1Y70.00%
Return 3Y-78.38%
Return 5Y-64.45%

Ownership

Insiders Held1.01%
Institutions Held64.32%
Institutions Float Held64.97%
Institutional HolderSharesReport Date
T. Rowe Price Investment Management, Inc.11,080,0052026-03-31
Bain Capital Life Sciences Investors, LLC9,677,1252026-03-31
Jennison Associates LLC8,970,5782026-03-31
Adage Capital Partners GP L.L.C.8,829,7582026-03-31
Millennium Management Llc5,903,2812026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLO $1.95 +2.63% -2.17 $673.05M 0.00%
AVIR $4.75 +1.06% -2.13 $380.13M 0.00%
CAPR $3.93 -5.76% -50.70 $227.59M 0.00%
EDIT $2.62 -2.24% -1.39 $256.50M 0.00%
HUMA $0.66 -1.79% -4.19 $110.81M 0.00%

About CABA

CABA is led by CEO Steven A. Nichtberger, publicly traded since 2019.

CABA stock trades at $2.71 with a market capitalization of $441.88M. The stock is valued at a price-to-earnings (P/E) ratio of -2.23, price-to-book of 3.14, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.26 and $4.23, and currently trades 35.9% below its 52-week high.

On profitability, CABA generates a return on equity (ROE) of -150.00%, return on capital employed of -153.57%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides